HighMark Wealth Management’s Heron Therapeutics HRTX Stock Holding History

HighMark Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42	Hold	100	–	–	﹤0.01%	554
2026 Q1	$80	Hold	100	–	–	﹤0.01%	542
2025 Q4	$130	Hold	100	–	–	﹤0.01%	570
2025 Q3	$126	Hold	100	–	–	﹤0.01%	592
2025 Q2	$207	Hold	100	–	–	﹤0.01%	587
2025 Q1	$220	Buy	+100	New	+$194	﹤0.01%	547
2020 Q3	–	Sell	-700	Closed	-$14K	–	457
2020 Q2	$14K	Hold	700	–	–	0.02%	163
2020 Q1	$8K	Hold	700	–	–	0.01%	166
2019 Q4	$16K	Buy	+700	New	+$15.5K	0.02%	151

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

HighMark Wealth Management's HRTX Position: Q2 2026 in Review

HighMark Wealth Management held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 100 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #554.

HighMark Wealth Management first reported a position in HRTX in Q4 2019 and has held it in 9 quarters since. The position peaked at $16K in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

HighMark Wealth Management held 100 shares of Heron Therapeutics worth $42 as of Q2 2026.
HighMark Wealth Management left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #554 holding.
HighMark Wealth Management first reported a position in Heron Therapeutics in Q4 2019 and has held it in 9 quarters since.
HighMark Wealth Management's Heron Therapeutics position peaked at $16K in Q4 2019.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.